¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"direct fluorescent antibody test"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • biliary drainage test
    ¾µ°³Áó¹èÃâ°Ë»ç, ´ãÁó¹èÃâ°Ë»ç
  • bactericidal test
    »ì±Õ°Ë»ç
  • bacteriophage neutralization test
    ¹ÚÅ׸®¿ÀÆÄÁöÁßÈ­½ÃÇè
  • biuret test
    ºä·¿°Ë»ç
  • blank test
    ºí·©Å©Å×½ºÆ®, °ø½ÃÇè, ´ëÁ¶½ÃÇè
  • bleeding time test
    ÃâÇ÷½Ã°£°Ë»ç
  • blood coagulation test
    Ç÷¾×ÀÀ°í°Ë»ç
  • blood sugar test
    Ç÷´ç°Ë»ç
  • blood test
    Ç÷¾×°Ë»ç
  • bone conduction test
    »ÀÀüµµ°Ë»ç, °ñÀüµµ°Ë»ç
  • balloon occlusion test
    dz¼±Æó¼â°Ë»ç
  • breath holding test
    ¼ûÂü±â°Ë»ç, È£ÈíÁßÁö°Ë»ç
  • bronchial challenge test
    ±â°üÁöÀ¯¹ß°Ë»ç
  • clearance test
    û¼ÒÀ²½ÃÇè
  • clock-drawing test
    ½Ã°è±×¸®±â°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • autohemolysis test
    ÀÚ°¡¿ëÇ÷½ÃÇè
  • bactericidal test
    »ì±Õ½ÃÇè
  • bacteriophage neutralization test
    ¹ÚÅ׸®¿ÀÆÄÁöÁßÈ­½ÃÇè
  • balloon occlusion test
    dz¼±Æó¼â°Ë»ç
  • basic secretion test
    ±âº»ºÐºñ°Ë»ç
  • basophil degranulation test
    È£¿°±â±¸Å»°ú¸³°Ë»ç
  • bead test
    ±¸½½½ÃÇè, ±¸½½°Ë»ç
  • bile solubility test
    ´ãÁó¿ëÇØµµ°Ë»ç
  • biliary drainage test
    ´ãÁó¹èÃâ°Ë»ç, ´ãÁó¹è¾×°Ë»ç
  • biological test
    »ý¹°ÇÐÀû½ÃÇè
  • blank test
    °ø½ÃÇè
  • bleeding time test
    ÃâÇ÷½Ã°£°Ë»ç
  • blocking test
    Â÷´Ü½ÃÇè
  • blood test
    Ç÷¾×°Ë»ç
  • blood coagulation test
    Ç÷¾×ÀÀ°í°Ë»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • hemagglutination inhibition antibody
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦Ç×ü.
  • hemolytic antibody
    ¿ëÇ÷Ç×ü.
  • heterogenic antibody
    ÀÌÁ¾Ç×ü.
  • heterologous antibody
    ÀÌÁ¾Ç×ü.
  • heterophil antibody
    ÀÌÁ¾Ä£È­¼º Ç×ü
  • heterophil(e) antibody
    ÀÌÁ¾Ä£È­(¼º)Ç×ü(ì¶ðúöÑûùàõù÷ô÷).
  • heterophil(e) antibody reaction
    ÀÌÁ¾Ä£È­(¼º) Ç×ü¹ÝÀÀ(¡­Úãëë).
  • homocytotropic antibody
    µ¿Á¾¼¼Æ÷ģȭ¼º Ç×ü.
  • homologous antibody
    »óµ¿Ç×ü.
  • hybrid antibody molecule
    ÇÏÀ̺긮µåÇ×üºÐÀÚ
  • hypersensitivity reactions,type ii(antibody-dependent cell-mediate cyt
    IIÇü
  • hypersensitivity, antibody-mediated
    Ç×ü¸Å°³ °ú¹Î¹ÝÀÀ
  • immobilizing antibody
    ¿îµ¿¾ïÁ¦Ç×ü.
  • incomplete antibody
    ºÒ¿ÏÀüÇ×ü.
  • incomplete antibody
    ºÒ¿ÏÀüÇ×ü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • antibody unit
    Ç×ü´ÜÀ§(ù÷ô÷Ó¤êÈ).
  • antibody unit
    Ç×ü´ÜÀ§(ù÷ô÷Ó¤êÈ).
  • antibody valence
    Ç×ü°áÇÕ°¡(¡­Ì¿ùêʤ).
  • antibody, Rh
    RhÇ×ü
  • antibody, blocking
    Â÷´ÜÇ×ü
  • antibody, cold
    ÇÑ·©Ç×ü
  • antibody, colostral
    ÃÊÀ¯Ç×ü
  • antibody, complement binding
    º¸Ã¼°áÇÕÇ×ü
  • antibody, complement fixing
    º¸Ã¼°áÇÕÇ×ü
  • antibody, cross-reacting
    ±³Â÷¹ÝÀÀÇ×ü
  • antibody, cytolytic
    ¼¼Æ÷¿ëÇØÇ×ü
  • antibody, cytophilic
    ¼¼Æ÷ģȭ¼ºÇ×ü
  • antibody, cytotoxic
    ¼¼Æ÷µ¶¼ºÇ×ü
  • antibody, cytotropic
    ¼¼Æ÷ģȭ¼ºÇ×ü
  • antibody, enzyme-labelled
    È¿¼ÒÇ¥ÁöÇ×ü
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 11
MA malignant arrhythmia; management and administration; mandelic acid; masseter; Master of Arts; matern...
PCA para-chloramphetamine; parietal cell antibody; passive cutaneous anaphylaxis; patient care assistant...
TA alkaline tuberculin; arterial tension; axillary temperature; tactile afferent; Takayasu arteritis; t...
FA   1) Fatty Acid
  2) Fluorescent Antibodies; Çü±¤ Ç×ü
DEAFF detection of early antigen fluorescent foci
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 11
IFA Immuno-fluorescent assay
MFI Mean fluorescent intensity
SIF Small Intensely Fluorescent
YFP Yellow Fluorescent Protein
BFP blue fluorescent protein
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • blood sugar test
    Ç÷´ç °Ë»ç
  • blood test
    Ç÷¾× °Ë»ç, Ç÷¾× °Ë»ç¹ý
    Áúº´ÀÇ Áø´Ü, Ä¡·á ¹× ¿¹ÈÄ ÆÇÁ¤À» ¸ñÀûÀ¸·Î Ç÷¾×ÀÇ °¢Á¾ ¼ººÐÀ» °Ë»çÇÏ´Â ÀÏ. ¸ö ÀüüÀÇ Àå±â³ª Á¶Á÷¿¡ º´º¯ÀÌ ÀÖÀ¸¸é ÀÌµé ¼ººÐ¿¡ º¯È­°¡ ÀÖ°Ô µÇ¾î Áø´Ü¿¡ Å« µµ¿òÀ» ÁØ´Ù. ©ç ÇüÅÂÇÐÀû °Ë»ç¹ý : Ç÷¾×ÀÇ ¼¼Æ÷ÇÐÀû ¹× ÀÌÇÐÀûÀÎ ¼ºÁú°ú »óŸ¦ °Ë»çÇÏ´Â °ÍÀ¸·Î¼­ äÇ÷ÇÏ¿© ÀûÇ÷±¸ ¼ö, Ç÷»ö¼Ò·®, ÀûÇ÷±¸ ¿ëÀû°ú À̵鿡¼­ °è»êµÇ´Â °è¼ö¿Í ¹éÇ÷±¸ ¼ö, Ç÷¼ÒÆÇ ¼ö, ¸Á»ó ÀûÇ÷±¸ ¼ö µîÀ» °Ë»çÇÏ°í ¶Ç Ç÷¾× ÇÑ ¹æ¿ïÀ» ½½¶óÀÌµå ±Û¶ó½º¿¡ ¾ã°Ô ¹Ù¸¥ °ÍÀ» ¿°»öÇÏ¿© ¹éÇ÷±¸ÀÇ Á¾·ù, °¢Á¾ Ç÷±¸ÀÇ ÁúÀû º¯È­¸¦ Á¶»çÇÑ´Ù. ¶Ç ÃâÇ÷ ½Ã°£, ÀÀ°í ½Ã°£, ¸ð¼¼Ç÷°ü ÀúÇ× µîÀ» °Ë»çÇØ¼­ ÃâÇ÷ °æÇâ, Ç÷¾× Áúȯ, °¨¿°Áõ µîÀÇ Áø´Ü°ú °¢Á¾ ÁúȯÀÇ °æ°ú¿Í ¿¹ÈÄ ÆÇÁ¤¿¡ Å« µµ¿òÀÌ µÈ´Ù. ©è »ýÈ­ÇÐÀû °Ë»ç¹ý : Ç÷¾× ¼ÓÀÇ ¿©·¯ ¼ººÐÀ» »ýÈ­ÇÐÀû ¹æ¹ýÀ¸·Î ÃøÁ¤ÇÏ´Â °ÍÀ¸·Î Ç÷û ´Ü¹éÁú
  • bone conduction test
    °ñÀüµµ ½ÃÇè
  • Bonsignore test
    º»½Ã±×³ë ½ÃÇè
  • bracelet test
    ¿Ï·û ½ÃÇè
  • breakdown test
    ÆÄ±« ½ÃÇè
  • breath holding test
    È£Èí ÁßÁö ½ÃÇè
  • Brucellosis test
    ºê·ç¼¿¶óÁõ ½ÃÇè
  • butyric acid test
    ³«»ê ½ÃÇè
  • Callaways test
    Ķ·¯¿þÀÌ ½ÃÇè
    »ó¿Ï°ñ Å»±¸ÀÇ ½ÃÇè¹ýÀ¸·Î, °ßºÀ¿¡¼­ °Üµå¶ûÀ̸¦ °ÅÃÄ ÃøÁ¤ÇÑ ¾î±ú µÑ·¹´Â Å»±¸µÈ ÂÊÀÌ ´õ Å©´Ù
  • candida test
    ĵµð´Ù ½ÇÇè
  • Cantanis test
    ĭŸ´Ï ½ÃÇè
  • capillary fragility test
    ¸ð¼¼°ü Ãë¾à¼º ½ÃÇè, ¸ð¼¼Ç÷°ü Ãë¾à¼º ½ÃÇè
    Á¤¸Æ Ç÷·ù¸¸À» ÃæºÐÈ÷ Â÷´ÜÇÒ ¼ö ÀÖµµ·Ï Ç÷¾Ð´ë¸¦ 5ºÐ°£ °­ÇÏ°Ô Á¹¶ó¸Ç ÈÄ¿¡ ÀÌ·Î ÀÎÇÏ¿© »ý±ä ÇǺÎÀÇ Á¡ÃâÇ÷ÀÇ ¼ö¸¦ ¼¼¾î ¸ð¼¼°üÀÇ Ãë¾à¼ºÀ» °Ë»çÇÏ´Â °Í.
  • capillary resistance test
    ¸ð¼¼Ç÷°ü ÀúÇ×¼º ½ÃÇè
  • Cappagnolis test
    İÆÄ³î¸® ½ÃÇè
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
IgM antibody capture ELISA Developed to impart significant improvement in assay specificity to indirect ELISA procedures for IgM isotype antibodies. Solid-phase support (usually microtitre plate wells) are coated with anti-human IgM antibodies capable of binding all IgM isotype antibodies present in the specimen. Reagent antigen is then added, followed by enzyme-labelled antigen-specific antibodies. If IgM antibodies specific for the antigen in question are present, the "sandwich" complex will result in enzymatic colour-change proportional to the concentration of IgM-specific antibody present. This technique appears to be the method of choice in many highly specific and more sensitive assays for IgM infectious disease antibodies.
Acronym: MAC ELISA
(05 Mar 2000)
immobilizing antibody Antibody, evoked during syphilitic infections, possessing specific affinity for Treponema pallidum, and which in the presence of complement immobilises the organism.
Synonym: immobilizing antibody, treponemal antibody.
(05 Mar 2000)
incomplete antibody An "incomplete" form of antibody that may coat antigen, but which according to the "lattice theory" does not have a second receptor for attachment to another molecule of antigen; in the case of Rh+ erythrocytes, such an anti-Rh antibody may coat the cells but not cause them to agglutinate in saline; however, agglutination does occur when such coated cells are suspended in serum or other protein media, such as albumin, therefore called serum agglutinin.
Synonym: incomplete antibody, inhibiting antibody.
(05 Mar 2000)
inhibiting antibody An "incomplete" form of antibody that may coat antigen, but which according to the "lattice theory" does not have a second receptor for attachment to another molecule of antigen; in the case of Rh+ erythrocytes, such an anti-Rh antibody may coat the cells but not cause them to agglutinate in saline; however, agglutination does occur when such coated cells are suspended in serum or other protein media, such as albumin, therefore called serum agglutinin.
Synonym: incomplete antibody, inhibiting antibody.
(05 Mar 2000)
thyroglobulin antibody <investigation> A serologic blood test which measures the antithyroglobulin antibodies in the blood.
Thyroglobulin is a protein found in thyroid tissue. It is the source of thyroid hormones in the body. The presence of antibodies to this protein can result in decreased thyroid gland function. A negative assay is considered normal.
Conditions where the assay may be positive include: lupus, rheumatoid arthritis, Hashimoto's thyroiditis, thyrotoxicosis, hypothyroidism, thyroid cancer, myxoedema, Sjogren's syndrome and autoimmune haemolytic anaemia.
(07 Mar 2000)
thyroid receptor antibody A test that measures the amount of an antibody (thyroid stimulating antibody) which is directed against a receptor for TSH on the thyroid gland. This antibody acts like TSH and stimulates the thyroid to produce excessive amounts of thyroid hormone. The presence of this antibody generally indicates Grave's disease (hyperthyroidism).
(27 Sep 1997)
thyroid stimulating antibody <endocrinology, immunology> Long acting thyroid stimulator is an autoantibody found in many cases of primary thyrotoxicosis which causes hyperplasia of the thyroid by undetermined mechanisms. Human thyroid stimulating immunoglobulin is a different antibody found in all or nearly all cases of primary thyrotoxicosis and may act by binding to the thyrotropin (TSH) receptor site, causing increased synthesis of thyroglobulin.
(18 Nov 1997)
toxoplasma antibody titre A test which measures the presence of antibodies against Toxoplasma in the blood. This test is used to detect congenital or postnatal toxoplasmosis or to screen pregnant women for the presence of Toxoplasma antibodies. The presence of antibodies before pregnancy probably protects the foetus against congenital toxoplasmosis. Antibodies against Toxoplasma that are developed during pregnancy may indicate a congenital infection (increased risk of birth defects and spontaneous abortion).
(27 Sep 1997)
treponema-immobilizing antibody Antibody, evoked during syphilitic infections, possessing specific affinity for Treponema pallidum, and which in the presence of complement immobilises the organism.
Synonym: immobilizing antibody, treponemal antibody.
(05 Mar 2000)
treponemal antibody Antibody, evoked during syphilitic infections, possessing specific affinity for Treponema pallidum, and which in the presence of complement immobilises the organism.
Synonym: immobilizing antibody, treponemal antibody.
(05 Mar 2000)
univalent antibody An "incomplete" form of antibody that may coat antigen, but which according to the "lattice theory" does not have a second receptor for attachment to another molecule of antigen; in the case of Rh+ erythrocytes, such an anti-Rh antibody may coat the cells but not cause them to agglutinate in saline; however, agglutination does occur when such coated cells are suspended in serum or other protein media, such as albumin, therefore called serum agglutinin.
Synonym: incomplete antibody, inhibiting antibody.
(05 Mar 2000)
fluorescein-conjugated antibody Refers to an antibody that has joined with a fluorescein molecule.
(09 Oct 1997)
Forssman antibody A heterogenetic antibody specific for the Forssman group of heterogenetic antigens.
Synonym: heterophil antibody, heterophile antibody.
(05 Mar 2000)
Forssman antigen-antibody reaction The combination of Forssman antibody with heterogenetic antigen of the Forssman type, as in the agglutination of sheep erythrocytes (which contain Forssman antigen) by serum from a person with infectious mononucleosis which contains Forssman antibody.
Synonym: Forssman reaction.
(05 Mar 2000)
lyme disease antibody A blood test which measures for the presence of Lyme disease antibodies. A nonreactive or serum titre of less than 1:256 is normal. A rising titre over time is more diagnostic. False positives due occur in those with rheumatoid arthritis and lupus.
(27 Sep 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 11
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 11
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 11
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 11
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 11
ÅëÇÕ°Ë»ö ¿Ï·á